The idea of ReliaTech was born and realized in 1999: Dr. Herbert Weich from the Helmholtz-Centre of Infection Research in Braunschweig- at that time GBF (German Research Centre for Biotechnology) - wanted to implement his long tempting idea: to put his expert knowledge in the field of growth factors and angiogenesis into the service of an improved supply of high-quality and reliable reagents for the research community.
Together with Dr. Bernhard Barleon who worked at the Clinic for Tumor Biology in Freiburg, Germany, at that time and Prof. Avner Yayon from the Weizman Institute of Science (WIS) in Israel and he founded ReliaTech GmbH (short for Receptor Ligand Technologies GmbH).
Receptor - ligand interactions: A central point in biological regulation now and then, making both - receptors and ligands - natural targets for researcher's interests.
The founders' aim: The company should become a supportive tool in the research chain by providing high-quality cost-effective reagents and research tools for the research community. The effective column of the business, however, should become the in-house production - enabling ReliaTech to offer individual solutions for individual needs.
2000: The launch of the company's first product - ReliaTech's anti-human soluble Flt-1 ELISA - marks the successful entry into ReliaTech's operating business.
Since then the company has undergone a continuous growth and development process leading into a growing portfolio of reagent offerings and sophisticated reagent development services for our customers.
In 2007 Dr. Volker Jäger from Helmholtz-Centre of Infection Research joins ReliaTech as additional stockholder and scientific advisor.
2009 is the year of an exciting developmental milestone of ReliaTech: The company's standing as established biotech company requires new surroundings and more space. ReliaTech moves from Braunschweig to the near-by city of Wolfenbüttel. The well-equipped new premises meet all demands of reagent production for our ambitious international clientele.